Drugs / Empagliflozin/Linagliptin/Metformin XR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02821910 | Jul → Oct 2016 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Empagliflozin/Linagliptin/Metformin XR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02821910 ↗ |
| Route | Oral | “Following Oral Administration” NCT02821910 ↗ |